Identification of Retinoic Acid Receptor Agonists as Potent Hepatitis B Virus Inhibitors via a Drug Repurposing Screen-Reference-Cited by-同舟云学术

Identification of Retinoic Acid Receptor Agonists as Potent Hepatitis B Virus Inhibitors via a Drug Repurposing Screen

Published:2018-12 Issue:12 Volume:62 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Li Baocun¹²,Wang Yang¹,Shen Fang¹²,Wu Min¹,Li Yaming¹,Fang Zhong¹,Ye Jianyu¹,Wang Li²,Gao Lu²,Yuan Zhenghong¹,Chen Jieliang¹

Affiliation:

1. Key Laboratory of Medical Molecular Virology, School of Basic Medical Sciences, Shanghai Medical College of Fudan University, Shanghai, China

2. Roche Innovation Center Shanghai, Shanghai, China

Abstract

Currently available therapies for chronic hepatitis B virus (HBV) infection can efficiently reduce viremia but induce hepatitis B surface antigen (HBsAg) loss in very few patients; also, these therapies do not greatly affect the viral covalently closed circular DNA (cccDNA). To discover new agents with complementary anti-HBV effects, we performed a drug repurposing screen of 1,018 Food and Drug Administration (FDA)-approved compounds using HBV-infected primary human hepatocytes (PHH).

Funder

National Science and Technology Major Project of China

National Natural Science Foundation of China

Shanghai Municipal Education Commission

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00465-18

Reference43 articles.

1. Hepatitis B cure: From discovery to regulatory approval